Literature DB >> 3995432

Effect of nifedipine and propranolol on blood flow, venous compliance and blood pressure in essential hypertension.

R I Ogilvie.   

Abstract

To determine the efficacy of nifedipine combined with propranolol in the treatment of hypertension, 23 patients with essential hypertension uncontrolled while they were receiving propranolol, 120 mg/d, entered a dose response trial of four 8-week periods while continuing propranolol therapy. Therapy during the four periods consisted respectively of a placebo, 30 mg/d of nifedipine, 30 or 60 mg/d of nifedipine, and 30 or 60 mg/d of nifedipine along with only 60 mg/d of propranolol. Studies of forearm blood flow and venous compliance were carried out in nine of the patients. Ten patients dropped out after the first period. The mean blood pressures while the patients were recumbent after the first, second and third periods were 163 +/- 17/100 +/- 6, 147 +/- 13/89 +/- 10 and 141 +/- 19/84 +/- 10 mm Hg respectively. There was no evidence of tolerance in the four patients who received 30 mg/d of nifedipine during the third period. There was a significant dose-diastolic pressure response (p less than 0.0006) without a change in heart rate in the eight who received 60 mg/d of nifedipine during this period. After 16 weeks of therapy with nifedipine 11 patients had a diastolic pressure less than 90 mm Hg while recumbent. While mean blood pressure and heart rate for the group were not significantly increased at the end of the fourth period, in three of the patients the diastolic pressure while recumbent increased to over 90 mm Hg. This suggests that 120 mg/d of propranolol is the minimum dose required for concomitant therapy. Adverse symptoms were mild and transient. Forearm plethysmography showed that nifedipine induced arteriolar but not venous dilation and that propranolol attenuated the vasodilator effect of nifedipine. The author concludes that nifedipine was safe and effective in combination with propranolol in this group of patients with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3995432      PMCID: PMC1345938     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  18 in total

1.  Beneficial effect of adding nifedipine to beta-adrenergic blocking therapy in angina pectoris.

Authors:  K Daly; G Bergman; M Rothman; L Atkinson; G Jackson; D E Jewitt
Journal:  Eur Heart J       Date:  1982-02       Impact factor: 29.983

2.  Relationship between the antihypertensive effect and steady-state plasma concentration of nifedipine given alone or in combination with a beta-adrenoceptor blocking agent.

Authors:  O Lederballe Pedersen; C K Christensen; E Mikkelsen; K D Rämsch
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

3.  Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade.

Authors:  K Aoki; S Kondo; A Mochizuki; T Yoshida; S Kato; K Kato; K Takikawa
Journal:  Am Heart J       Date:  1978-08       Impact factor: 4.749

4.  Cardiovascular effects of acebutolol and hydrochlorothiazide in essential hypertension.

Authors:  R I Ogilvie; J H Nadeau
Journal:  Hypertension       Date:  1982 Mar-Apr       Impact factor: 10.190

5.  Management of severe hypertension with nifedipine in combination with clonidine or propranolol.

Authors:  Y Imai; K Abe; Y Otsuka; N Irokawa; M Yasujima; K Saito; Y Sakurai; S Chiba; T Ito; M Sato; T Haruyama; Y Miura; K Yoshinaga
Journal:  Arzneimittelforschung       Date:  1980

6.  Combined acebutolol/nifedipine therapy in patients with chronic coronary artery disease: additional improvement of ischemia-induced left ventricular dysfunction.

Authors:  M Pfisterer; J Müller-Brand; F Burkart
Journal:  Am J Cardiol       Date:  1982-04-01       Impact factor: 2.778

7.  Laboratory distinction between essential and secondary hypertension by measurement of erythrocyte cation fluxes.

Authors:  R P Garay; J L Elghozi; G Dagher; P Meyer
Journal:  N Engl J Med       Date:  1980-04-03       Impact factor: 91.245

8.  Effects of nifedipine on resistance vessels, arteries and veins in man.

Authors:  B F Robinson; R J Dobbs; C R Kelsey
Journal:  Br J Clin Pharmacol       Date:  1980-11       Impact factor: 4.335

Review 9.  Is a circulating sodium transport inhibitor involved in the pathogenesis of essential hypertension?

Authors:  G A MacGregor; H E de Wardener
Journal:  Clin Exp Hypertens       Date:  1981       Impact factor: 1.749

10.  Nifedipine and propranolol: a beneficial drug interaction.

Authors:  H J Dargie; P G Lynch; D M Krikler; L Harris; S Krikler
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

View more
  1 in total

Review 1.  Calcium channel antagonism and beta blockade in combination--a therapeutic alternative in cardiovascular disorders. A review.

Authors:  J N Lessem; B N Singh
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.